FBR Capital Starts Allscripts-Misys Healthcare (MDRX) at Market Perform; Merged Healthcare IT Co. Has Strong Base, But Plenty of Work to Do
Tweet Send to a FriendGet Alerts MDRX Hot Sheet
Price: $13.96 --0%
Rating Summary:
11 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 13
Rating Summary:
11 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 13
Trade MDRX Now!
FBR Capital initiates coverage on Allscripts-Misys Healthcare (NASDAQ: MDRX) with a Market Perform. PT $22.
FBR analyst says, "Allscripts has combined with Eclipsys to become one of the largest pure-play healthcare information technology (HIT) companies in the industry. Both companies had impressive footprints in the ambulatory and acute hospital spaces, respectively. The coupling gives the new entity considerable opportunity to crosssell its solutions and solidifies Allscripts as a long-term player in a competitive market. We expect Allscripts to continue to market itself as having pervasive reach across the healthcare IT market and an appetite for growth. MDRX’s current market price leaves some room for upside but factors in much of the positives, as well as the risks, associated with the newly combined entity."
For more ratings news on Allscripts-Misys Healthcare click here and for the rating history of Allscripts-Misys Healthcare click here.
Shares of Allscripts-Misys Healthcare closed at $21.38 yesterday, with a 52 week range of $15.65-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
FBR analyst says, "Allscripts has combined with Eclipsys to become one of the largest pure-play healthcare information technology (HIT) companies in the industry. Both companies had impressive footprints in the ambulatory and acute hospital spaces, respectively. The coupling gives the new entity considerable opportunity to crosssell its solutions and solidifies Allscripts as a long-term player in a competitive market. We expect Allscripts to continue to market itself as having pervasive reach across the healthcare IT market and an appetite for growth. MDRX’s current market price leaves some room for upside but factors in much of the positives, as well as the risks, associated with the newly combined entity."
For more ratings news on Allscripts-Misys Healthcare click here and for the rating history of Allscripts-Misys Healthcare click here.
Shares of Allscripts-Misys Healthcare closed at $21.38 yesterday, with a 52 week range of $15.65-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Atmel (ATML) at Buy
- BMO Capital Starts IHS Inc. (IHS) at Outperform
- Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Eclipsys/Allscripts Merger
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
